Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $116.31, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Price: $104.30, Change: $+5.09, Percent Change: +5.13%
Workiva (WK) reported Q1 adjusted earnings late Tuesday of $0.77 per diluted share, up from $0.14 a year earlier.Analysts polled by FactSet expected $0.65.Revenue for the three months ended March 31 rose to $247.3 million from $206.3 million a year earlier.Analysts surveyed by FactSet expected $245.2 million.Workiva expects Q2 adjusted EPS of $0.62 to $0.65 on revenue of $250 million to $252 million. Analysts expect EPS of $0.52 on revenue of $252.1 million.The company expects full-year adjusted EPS of $2.85 to $2.95 on revenue of $1.037 billion to $1.041 billion. Analysts expect EPS of $2.71 on revenue of $1.038 billion.Workiva shares fell 4.4% in after-hours trading.
SSR Mining (SSRM) reported Q1 adjusted earnings late Tuesday of $1.15 per diluted share, up from $0.41 a year earlier.Analysts polled by FactSet expected $0.84.Revenue in the three months ended March 31 rose to $581.8 million from $316.6 million a year earlier.Four analysts surveyed by FactSet expected $536.4 million.SSR Mining shares rose 8% in after-hours trading.
Everus Construction Group (ECG) reported Q1 earnings late Tuesday of $1.14 per diluted share, up from $0.72 a year earlier.Analysts surveyed by FactSet expected $0.81.Revenue for the three months ended March 31 rose to $1.04 billion from $826.6 million a year earlier.Analysts polled by FactSet expected $933.8 million.The company raised full-year revenue guidance to $4.3 billion to $4.4 billion from the prior forecast of $4.1 billion to $4.2 billion.Analysts expect $4.23 billion.Everus shares rose 4.2% in after-hours trading.